Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone

Diabetic Medicine

Volumn 21, Issue 12, 2004, Pages 1280-1287

  Hällsten, Kirsti ^a   Virtanen, K A ^a   Lonnqvistt F ^b   Janatuinen, T ^a   Turiceanu, M ^a   Ronnemaa T ^a   Viikari, J ^a   Lehtimaki T ^c   Knuuti, J ^a   Nuutila, P ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Glucose; Imaging; Myocardial metabolism; Positron emission tomography; Rosiglitazone

Indexed keywords

FATTY ACID; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; INTERLEUKIN 6; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; ROSIGLITAZONE;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE METABOLISM; HEART VENTRICLE REMODELING; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL;

DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; PPAR GAMMA; STATISTICS, NONPARAMETRIC; STIMULATION, CHEMICAL; THIAZOLIDINEDIONES;

EID: 10244225267     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01332.x     Document Type: Article

References (51)

1. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
2. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
3. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes. Circ Res 2000; 87: 596-602.
4. Altiok S, Xu M, Spiegelman BM. PPARγ induces cell cycle withdrawal, inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 1997; 11: 1987-98.
5. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N et al. Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002; 105: 1240-1246.
6. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001; 104: 1670-1675.
7. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-693.
8. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J et al. Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126-3132.
9. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
10. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001; 1: 181-193.
11. Scheibert HR, Buxton D. Insights into coronary artery disease gained from metabolic imaging. Circulation 1988; 78: 496-505.
12. Oakes ND, Kennedy CJ, Jenkins AB, Layburt DR, Chisholm DJ, Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43: 1203-1210.
13. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 2002; 51: 1110-1117.
14. Fischer Y, Thomas J, Rosen P, Kammermeier H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. Endocrinology 1995; 136: 412-420.
15. Utriainen T, Takala T, Luotolahti M, Rönnemaa T, Laine H, Ruotsalainen U et al. Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia 1998; 41: 555-559.
16. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-590.
17. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 1992; 89: 1767-1774.
18. Ng CK, Soufer R, McNulty PH. Effect of hyperinsulinemia on myocardial fluorine-18-FDG uptake. J Nucl Med 1998; 39: 379-383.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
20. Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002; 51: 3479-3485.
21. Virtanen KA, Hällsten K, Parkkola R, Janatuinen T, Lönnqvist F, Viljanen T et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in Type 2 diabetic subjects. Diabetes 2003; 52: 283-290.
22. 18F]-fluoro-2-deoxy-D-glucose using amino-polyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-238.
23. Alenius S, Ruotsalainen U. Bayesian image reconstruction for emission tomography based on median root prior. Eur J Nucl Med 1997; 24: 258-265.
24. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897-916.
25. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 1979; 3: 299-308.
26. Henze E, Huang SC, Ratib O, Hoffman E, Phelps ME, Schelbert HR. Measurements of regional tissue and blood-pool radiotracer concentrations from serial tomographic images of the heart. J Nucl Med 1983; 24: 987-996.
27. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
29. Eda S, Kaufmann J, Roos W, Pohl S. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal 1998; 12: 137-144.
30. Yakubu-Madus FE, Stephens TW, Johnson WT. Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione. Diabetes Obes Metab 2000; 2: 155-163.
31. Racette SB, Davis AO, McGill JB, Klein S. Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus. Metabolism 2002; 51: 169-174.
32. Reaven GM, Johnston P, Hollenbeck CB, Skowronski R, Zhang JC, Goldfine ID et al. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 1992; 74: 1020-1026.
33. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
34. Randle PJ, Newsholme EA, Garland PB. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 1964; 93: 652-665.
35. Knuuti MJ, Mäki M, Yki-Järvinen H, Voipio-Pulkki LM, Härkönen R, Haaparanta M et al. The effect of insulin and FFA on myocardial glucose uptake. J Mol Cell Cardiol 1995; 27: 1359-1367.
36. Wisneski JA, Gertz EW, Neese RA, Gruenke LD, Morris DL, Craig JC. Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest 1985; 76: 1819-1827.
37. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Diabet Med 2002; 19: 939-943.
38. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
39. Mehrabi MR, Thalhammer T, Haslmayer P, Glogar HD, Wieselthaler G, Humpeler S et al. The peroxisome proliferator-activated receptor γ (PPARγ) is highly expressed in human heart ventricles. Biomed Pharmacother 2002; 56: 407-410.
40. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ et al. Peroxisome proliferator-activated receptor (PPAR)α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 2003; 92: 518-524.
41. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-872.
42. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49: 827-831.
43. Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M et al. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 2002; 51: 30-36.
44. Dutta K, Podolin DA, Davidson MB, Davidoff AJ. Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 2001; 50: 1186-1192.
45. Wu MS, Johnston P, Sheu WH, Hollenbeck CB, Jeng CY, Goldfine ID et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13: 1-8.
46. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: E55.
47. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
48. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928.
49. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059-4067.
50. Nuutila P, Knuuti MJ, Mäki M, Laine H, Ruotsalainen U, Teräs M et al. Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using positron emission tomography. Diabetes 1995; 44: 31-36.
51. Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000; 101: 1165-1171.